This study shows that synovial sarcoma cells, with a loss in P16INK4A, are sensitive to palbociclib treatment, indicating that palbociclib may be a potential therapeutic drug to treat synovial sarcoma. The gene discussed is CDKN2A; the disease is synovial sarcoma.